Geron Corporation — Third Quarter 2026 Earnings Summary

Geron Corporation reported third-quarter 2026 net product revenue of $60.1 million for RYTELO, representing a 5% increase from the previous quarter. The company achieved a net income of $1.4 million for the period, driven by higher revenues and reduced operating expenses compared to the same period in 2025. Geron reiterated its full-year 2026 RYTELO revenue guidance between $220 million and $240 million while lowering its total operating expense forecast to the $220 million to $230 million range. Additionally, the company initiated a gated commercial launch to expand RYTELO access to eligible patients in targeted European markets, with availability in Germany expected by the end of the year.